Literature DB >> 31234023

Traditional Chinese medicine combined with hepatic targeted drug delivery systems: A new strategy for the treatment of liver diseases.

Zhe Ma1, Bing Zhang1, Yuqi Fan2, Meng Wang1, Dereje Kebebe3, Jiawei Li4, Zhidong Liu5.   

Abstract

Liver diseases are clinically common and present a substantial public health issue. Many of the currently available drugs for the treatment of liver diseases suffer from limitations that include low hepatic distribution, lack of target effects, poor in vivo stability and adverse effects on other organs. Consequently, conventional treatment of hepatic diseases is ineffective. TCM is commonly used in the treatment of liver diseases worldwide, particularly in China, and has advantages over conventional therapy. HTDDS can be designed to enhance clinical efficacy in the treatment of liver diseases. We have conducted an extensive review of 335 studies reported since 1964. These included about 166 references involving the treatment of liver diseases with TCM (covering active components of TCM, single TCM and Chinese medicine formulas), 169 reports on HTDDS and background studies on liver-related diseases. Here we review the long history of TCM in the treatment of liver diseases.We have also reviewed the status of studies on active components of TCM using nanotechnology-based targeted delivery systems to provide support for further research and development of TCM-based targeted preparations for the treatment of liver disease.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Chinese herb; Hepatic targeted drug delivery system; Liver diseases; Nanotechnology; Natural drug; Traditional Chinese medicine

Year:  2019        PMID: 31234023     DOI: 10.1016/j.biopha.2019.109128

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

Review 1.  Advances in Nano-Enabled Platforms for the Treatment of Depression.

Authors:  Fadzai P Mutingwende; Pierre P D Kondiah; Philemon Ubanako; Thashree Marimuthu; Yahya E Choonara
Journal:  Polymers (Basel)       Date:  2021-04-29       Impact factor: 4.329

2.  Systematic Elucidation of the Potential Mechanism of Erzhi Pill against Drug-Induced Liver Injury via Network Pharmacology Approach.

Authors:  Shao-Jie Huang; Fei Mu; Fei Li; Wen-Jun Wang; Wei Zhang; Lu Lei; Yang Ma; Jing-Wen Wang
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-07       Impact factor: 2.629

3.  Network Pharmacology Approach to Explore the Potential Mechanisms of Jieduan-Niwan Formula Treating Acute-on-Chronic Liver Failure.

Authors:  Jiajun Liang; Mengli Wu; Chen Bai; Chongyang Ma; Peng Fang; Weixin Hou; Xiaoyi Wei; Qiuyun Zhang; Yuqiong Du
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-30       Impact factor: 2.629

4.  Enhanced Anticancer Efficacy of Dual Drug-Loaded Self-Assembled Nanostructured Lipid Carriers Mediated by pH-Responsive Folic Acid and Human-Derived Cell Penetrating Peptide dNP2.

Authors:  Zhe Ma; Jiaxin Pi; Ying Zhang; Huan Qin; Bing Zhang; Nan Li; Zheng Li; Zhidong Liu
Journal:  Pharmaceutics       Date:  2021-04-22       Impact factor: 6.321

5.  Detoxification II Prescription Suppresses the Th-17/IL-17 Inflammatory Axis to Improve the Liver Function of ACLF-Rats via Inactivating the P38MAPK Pathway.

Authors:  Qinglan Shi; Wenjie Bai; Dewen Mao; Yueqiao Chen; Kejing Wang; Hua Qiu; Jinyu Wu
Journal:  J Healthc Eng       Date:  2021-12-03       Impact factor: 2.682

6.  Network Pharmacology and Molecular Docking Elucidate the Pharmacological Mechanism of the OSTEOWONDER Capsule for Treating Osteoporosis.

Authors:  Jiashuang Fan; Jianli Zhou; Zhuan Qu; Hangya Peng; Shuhui Meng; Yaping Peng; Tengyan Liu; Qiu Luo; Lifen Dai
Journal:  Front Genet       Date:  2022-02-28       Impact factor: 4.599

Review 7.  Nucleic acids and proteins carried by exosomes from various sources: Potential role in liver diseases.

Authors:  Danna Xie; Baolin Qian; Xun Li
Journal:  Front Physiol       Date:  2022-09-23       Impact factor: 4.755

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.